Drug Monograph

Drug/Drug Class:	**Aimovig® (erenumab-aooe) injection / Calcitonin Gene Related Peptide Inhibitors**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Aimovig® is now available in a single-dose prefilled SureClick® autoinjector containing 140 mg erenumab per ml.
Manufacturer:	Amgen Inc., Thousand Oaks, CA 91320
Indications:	Aimovig® is indicated for the preventive treatment of migraine in adults.
Costs:	$575 per 140 mg autoinjector of Aimovig®. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Preferred ☐ Appropriate Indications ☐ Under Solicitation

Prepared By: Luke Boehmer PharmD
Date: May 31, 2019

© 2019 Conduent Business Services, LLC All Rights Reserved.